A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503071-28-00

Acronym

ARC-10

Enrollment

106

Registered

2023-11-22

Start date

2023-08-31

Completion date

2025-01-10

Last updated

2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Squamous Non-small cell Lung Cancer

Brief summary

Overall survival (OS)

Detailed description

PFS according to RECIST v1.1 by blinded independent central review, and confirmed ORR according to RECIST v1.1 as assessed by BICR., Presence of treatment-emergent adverse events, and Changes in vital signs measurements and clinical laboratory parameters, Time to first symptom deterioration in NSCLC-SAQ total score

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGDOMVANALIMAB

DRUGAB122 (Zimberelimab)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Secondary

Measure	Time frame
PFS according to RECIST v1.1 by blinded independent central review, and confirmed ORR according to RECIST v1.1 as assessed by BICR., Presence of treatment-emergent adverse events, and Changes in vital signs measurements and clinical laboratory parameters, Time to first symptom deterioration in NSCLC-SAQ total score	—

Countries

France, Greece, Ireland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026